Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Shanghai Pharmaceuticals Holding Co ( (HK:2607) ) has shared an update.
Shanghai Pharmaceuticals announced the completion of an equity adjustment involving the transfer of the entire equity interest in Shanghai Industrial Investment (Holdings) Co. (SIIC) from its de facto controller, Shanghai SASAC, to Golden Bell, confirming that the transaction does not alter the company’s controlling shareholder structure or the identity of its ultimate controller. Following the completion of the adjustment and the latest share purchase plan, SIIC and its subsidiaries now hold 498,588,000 A and H shares, representing 13.45% of the company’s issued share capital, signalling a consolidated but stable ownership position that preserves governance continuity for investors and other stakeholders.
The most recent analyst rating on (HK:2607) stock is a Buy with a HK$13.00 price target. To see the full list of analyst forecasts on Shanghai Pharmaceuticals Holding Co stock, see the HK:2607 Stock Forecast page.
More about Shanghai Pharmaceuticals Holding Co
Shanghai Pharmaceuticals Holding Co., Ltd. is a major Chinese pharmaceutical group engaged in the production, distribution and retail of medicines and healthcare products, serving both domestic and international markets through A- and H-share listings in Shanghai and Hong Kong.
Average Trading Volume: 2,747,135
Technical Sentiment Signal: Sell
Current Market Cap: HK$66.02B
Learn more about 2607 stock on TipRanks’ Stock Analysis page.